Table 2.
Univariate analysis of patient and treatment characteristics on clinical results for very elderly EC
| Characteristics | No. of patients (%) | 2‐year OS | 2‐year LRFFS | 2‐year DMFS |
|---|---|---|---|---|
| Age (years) (median, range) | 79 (75–91) | P = 0.373 | P = 0.057 | P = 0.068 |
| <80 | 82 (55.0%) | 55.2% | 62.2% | 92.5% |
| ≥80 | 67 (45.0%) | 46.6% | 46.1% | 80.0% |
| Sex | P = 0.398 | P = 0.849 | P = 0.720 | |
| Male | 97 (65.1%) | 48.8% | 54.2% | 84.7% |
| Female | 52 (34.9%) | 55.8% | 56.1% | 86.3% |
| Comorbidities | P = 0.438 | P = 0.217 | P = 0.517 | |
| No | 86 (57.7%) | 48.0% | 51.0% | 79.9% |
| Yes | 63 (42.3%) | 55.7% | 60.1% | 83.3% |
| ECOG performance status | P = 0.565 | P = 0.333 | P = 0.364 | |
| 0–1 | 142 (95.3%) | 51.6% | 55.6% | 84.6% |
| 2–3 | 7 (4.7%) | 42.9% | 34.3% | 100.0% |
| NRI before RT | P = 0.012 | P = 0.093 | P = 0.011 | |
| <100 | 54 (36.2%) | 44.8% | 50.0% | 74.1% |
| ≥100 | 95 (63.8%) | 60.1% | 63.3% | 91.7% |
| NLR before RT | P < 0.001 | P = 0.002 | P = 0.787 | |
| <2.5 | 87 (58.4%) | 65.2% | 64.1% | 87.8% |
| ≥2.5 | 62 (41.2%) | 34.0% | 39.6% | 87.1% |
| Primary tumor location | P = 0.446 | P = 0.454 | P = 0.476 | |
| Upper–middle | 86 (57.7%) | 48.4% | 51.6% | 86.7% |
| Middle–lower | 63 (42.3%) | 53.8% | 57.4% | 82.3% |
| Primary tumor length (cm) | P = 0.354 | P = 0.672 | P = 0.780 | |
| <6 | 63 (42.3%) | 45.5% | 50.2% | 82.1% |
| ≥6 | 86 (57.7%) | 55.5% | 57.2% | 86.9% |
| AJCC stage | P = 0.006 | P < 0.001 | P = 0.050 | |
| I–II | 64 (43.0%) | 64.7% | 73.8% | 91.5% |
| III | 85 (57.0%) | 41.2% | 39.2% | 80.8% |
| T stage | P = 0.377 | P = 0.226 | P = 0.280 | |
| 1–2 | 18 (12.1%) | 61.1% | 68.8% | 93.3% |
| 3–4 | 131 (87.9%) | 49.6% | 52.6% | 83.8% |
| N status | P = 0.389 | P = 0.082 | P = 0.192 | |
| Negative | 93 (62.4%) | 54.6% | 62.1% | 87.9% |
| Positive | 56 (37.6%) | 45.9% | 42.9% | 80.8% |
| Range of CTV | P = 0.640 | P = 0.502 | P = 0.819 | |
| IFI | 124 (83.2%) | 52.1% | 55.8% | 85.1% |
| ENI | 25 (16.8%) | 46.8% | 50.1% | 86.7% |
| Fraction dose (Gy) | P = 0.495 | P = 0.654 | P = 0.804 | |
| <2 | 32 (21.5%) | 45.9% | 51.2% | 84.1% |
| ≥2 | 117 (78.5%) | 52.6% | 55.6% | 85.6% |
| Total dose for PGTV (Gy) | P = 0.055 | P = 0.018 | P = 0.552 | |
| <60 | 26 (17.4%) | 32.2% | 37.3% | 89.3% |
| ≥60 | 123 (82.6%) | 55.0% | 58.0% | 84.4% |
| Total dose for PTV (Gy) | P = 0.295 | P = 0.530 | P = 0.390 | |
| ≤50 | 32 (21.5%) | 45.5% | 51.5% | 95.5% |
| >50 | 117 (78.5%) | 52.6% | 54.9% | 82.6% |
| Chemotherapy | P = 0.695 | P = 0.310 | P = 0.009 | |
| No | 85 (57.0%) | 50.5% | 50.6% | 75.9% |
| Yes | 64 (43.0%) | 52.7% | 51.0% | 92.2% |
AJCC, American Joint Committee on Cancer; DMFS, distance metastasis‐free survival; ECOG, Eastern Cooperative Oncology Group; ENI, elective nodal irradiation; IFI, involved field irradiation; LRFFS, local–regional failure‐free survival; NRI, nutritional risk index; NLR, neutrophil–lymphocyte ratio; OS, overall survival; PGTV, planning gross tumor volume; PTV: planning target volume; RT, radiotherapy.